Choi Jung Ho, Hong Young Ok, Kim Hyo-Jeong, Jung Ah Ra
Department of Otorhinolaryngology-Head and Neck Surgery, Nowon Eulji Medical Center, Eulji University School of Medicine, 68 Hangeulbiseok-Ro, Nowon-gu, Seoul, 01830, Republic of Korea.
Department of Pathology, Nowon Eulji Medical Center, Eulji University School of Medicine, Seoul, Republic of Korea.
Thyroid Res. 2021 Nov 19;14(1):24. doi: 10.1186/s13044-021-00115-z.
Lithium use causes goiter by increasing serum thyroid-stimulating hormone levels through the inhibition of thyroid hormone release. However, there are no reports of poorly differentiated thyroid carcinoma resulting from lithium-induced goiter. Herein, we report the case of a patient with schizophrenia who developed poorly differentiated thyroid carcinoma arising from a lithium-induced goiter.
A 61-year-old woman who was taking lithium for schizophrenia, visited the thyroid-endocrine center with a 10 × 12 cm anterior neck mass. She had a slowly growing goiter approximately 30 years ago; however, when she came to the hospital for diabetes diagnosis 2 years ago, she had no accompanying symptoms and refused evaluation. Three months before her visit, her dysphagia and dyspnea worsened as the size of her goiter increased rapidly. A neck ultrasound and enhanced thyroid computed tomography (CT) examination revealed a 10.9 × 9.2 × 12.8 cm size multi-lobulated mass on the right thyroid gland, leading to a leftward deviation of the trachea. Diagnostic total thyroidectomy was performed, and microscopic findings and immunohistochemical staining results indicated poorly differentiated thyroid carcinoma (PDTC) in the right thyroid mass. Mutation analyses for BRAF and the telomerase reverse transcriptase (TERT) promoter was performed. No BRAF gene mutations were detected; however, TERT promoter C228T point mutation was present in the PDTC. The patient underwent radioactive iodine therapy two months after the surgery. At a recent follow-up 4 months postoperatively, she was taking thyroid hormone replacement and remained in a relatively good health with a serum thyroglobulin level of 0.55 ng/ml.
Thyroid examination of psychiatric patients who develop goiter due to long-term lithium treatment should be monitored regularly, and appropriate investigations and surgery should be performed in a timely manner if the goiter is growing rapidly.
锂的使用通过抑制甲状腺激素释放增加血清促甲状腺激素水平,从而导致甲状腺肿大。然而,尚无锂诱导的甲状腺肿大导致低分化甲状腺癌的报道。在此,我们报告一例因锂诱导的甲状腺肿大而发生低分化甲状腺癌的精神分裂症患者。
一名61岁因精神分裂症服用锂的女性,因前颈部10×12cm肿物就诊于甲状腺内分泌中心。大约30年前她患有缓慢生长的甲状腺肿大;然而,2年前她因糖尿病诊断前来医院时,没有伴随症状且拒绝评估。此次就诊前3个月,随着甲状腺肿大迅速增大,她出现吞咽困难和呼吸困难加重。颈部超声和增强甲状腺计算机断层扫描(CT)检查显示右甲状腺有一个10.9×9.2×12.8cm大小的多叶状肿物,导致气管向左移位。进行了诊断性全甲状腺切除术,显微镜检查结果和免疫组化染色结果表明右甲状腺肿物为低分化甲状腺癌(PDTC)。对BRAF和端粒酶逆转录酶(TERT)启动子进行了突变分析。未检测到BRAF基因突变;然而,在PDTC中存在TERT启动子C228T点突变。患者术后2个月接受了放射性碘治疗。在术后4个月的最近一次随访中,她正在接受甲状腺激素替代治疗,健康状况相对良好,血清甲状腺球蛋白水平为0.55ng/ml。
对于因长期锂治疗而出现甲状腺肿大的精神科患者,应定期监测甲状腺检查,如果甲状腺肿大迅速生长,应及时进行适当的检查和手术。